![Barry Simon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 21 M $ al 31/05/2026
Barry J. Simon ocupa el cargo de presidente, presidente y director ejecutivo de Brink Biologics, Inc. y director y jefe de asuntos corporativos de ImmunityBio, Inc. También forma parte del consejo de Cue Biopharma, Inc. (ex presidente) y Viracta Therapeutics, Inc. En el pasado, el Dr. Simon ocupó el cargo de Vicepresidente de Roche Holding AG y Vicepresidente de Roche Diagnostics Corp. (una filial de Roche Holding AG), Vicepresidente de HealthPro BioVentures LLC, Vicepresidente de North Sound Capital LLC, Vicepresidente de Asuntos Clínicos y Regulatorios de iTherX Pharmaceuticals, Inc, Presidente, Director y Jefe Administrativo de NantKwest, Inc y Vicepresidente de Immunomedics, Inc. El Dr. Simon se doctoró en la State University of New York at Downstate Medical Center.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IMMUNITYBIO INC 0,27 % | 04/06/2026 | 2.827.788 ( 0,27 % ) | 21 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| IMMUNITYBIO, INC. | Director/Miembro de la Junta | 01/01/2007 |
Brink Biologics, Inc.
 Brink Biologics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Director Ejecutivo | 01/03/2015 |
| Empresas | Cargo | Fin |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Director/Miembro de la Junta | 18/12/2024 |
| CUE BIOPHARMA, INC. | Presidente | - |
| IMMUNITYBIO, INC. | Director Ejecutivo | 01/03/2015 |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Director/Miembro de la Junta | 01/11/2020 |
Roche Diagnostics Corp.
 Roche Diagnostics Corp. Medical SpecialtiesHealth Technology Develops and produces medical tests and digital tools | Corporate Officer/Principal | 01/12/2004 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 15 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of cancer | Health Technology |
Roche Holding AG
 Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics | Health Technology |
iTherX Pharmaceuticals, Inc.
 iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services Engages in the discovery and development of drugs and therapies | Distribution Services |
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Develops and commercializes dermatology products | Health Technology |
NantKwest, Inc.
 NantKwest, Inc. BiotechnologyHealth Technology Develops and produces cancer treatment products | Health Technology |
Roche Diagnostics Corp.
Roche Diagnostics Corp. Medical SpecialtiesHealth Technology Develops and produces medical tests and digital tools | Health Technology |
HealthPro BioVentures LLC
 HealthPro BioVentures LLC Investment ManagersFinance HealthPro BioVentures serves the biotechnology, biomedical, healthcare and pharmaceutical sectors. Their purpose is to define, enhance and realize value for their clients by leveraging their experience, resources and network of relationships. The firm seeks to provide unparalleled services to meet the needs of the life sciences sector, from large corporate entities to emerging companies. HealthPro originally emerged from DavosPharma. They draw on extensive contacts through their relationships and association with DavosPharma. As a result, HealthPro has a network of both buy-side and sell-side healthcare opportunities. HealthPro BioVentures' services include the development of strategic and tactical themes and target lists of potential partners, access to their vast, proprietary library of available compounds, assisting with presentations and due diligence dossiers, analysis of the synergies of potential strategic partners, advising on structure, timing and pricing of transactions and assisting with negotiation, documentation and closing of transactions. HealthPro targets potential partners and investors to assist both public and private companies who are looking to acquire a strategic target company or product. The firm's portfolio of services allows them to represent life sciences companies that are either interested in being acquired or interested in investing specific assets. In both by-side and sell-side transactions, their focus is on developing transactions that are mutually beneficial to both the buyer and the seller. | Finance |
State University of New York at Downstate Medical Center
 State University of New York at Downstate Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
North Sound Capital LLC
 North Sound Capital LLC Investment ManagersFinance North Sound is a global long/short equity hedge fund manager. Though not limited by sector, they tend to focus on large-cap companies in the finance, communications, retail, energy and consumer services sectors. | Finance |
Cue Biopharma, Inc.
 Cue Biopharma, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Health Technology |
Brink Biologics, Inc.
Brink Biologics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Viracta Therapeutics, Inc.
 Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
ImmunityBio, Inc.
 ImmunityBio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for immunogenic mechanisms for defeating cancer and infectious disease | Health Technology |
Roche Labs |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
